Interleukin 9 (IL-9) is a γ c -family cytokine that is highly produced by T-helper 9 (Th9) cells and regulates a range of immune responses, including allergic inflammation. Here we show that IL-2-JAK3-STAT5 signaling is required for Th9 differentiation, with critical STAT5 binding sites in the Il9 (the gene encoding IL-9) promoter. IL-2 also inhibited B cell lymphoma 6 (BCL6) expression, and overexpression of BCL6 impaired Th9 differentiation. In contrast, IL-21 induced BCL6 and diminished IL-9 expression in wild-type but not Bcl6 −/− cells, and Th9 differentiation was increased in Il21
T cells can differentiate into an array of specialized T-helper populations, including Th1 cells, which mediate antiviral responses; Th2 cells, which mediate host defense to parasites and allergic inflammation; and Th17 cells, which are involved in inflammatory processes and diseases such as psoriasis and inflammatory bowel disease (1) (2) (3) (4) (5) . Th9 cells are a population of cells differentiated in the presence of IL-4 and TGF-β to secrete IL-9 and mediate allergic inflammation and immunity to intestinal parasites (6) (7) (8) (9) . The IL-9 receptor consists of IL-9R and the common cytokine receptor γ chain, γ c , which is shared by the receptors for IL-2, IL-4, IL-7, IL-15, and IL-21 (10) and mutated in humans with X-linked severe combined immunodeficiency (11) . IL-9R is broadly expressed, including on hematopoietic progenitors, mast cells, macrophages, dendritic cells, B cells, airway epithelial cells, immature neurons, eosinophils, natural killer T (NKT) cells, natural killer (NK) cells, Th9 cells, Th17 cells, and Treg cells (6-9, 12, 13) . This distribution helps to explain diverse actions of IL-9. IL-9 increases CD4
+ T-cell growth, IgE production by B cells, Treg function, Th17 differentiation, mast cell growth and survival, expression of FceR1α, production of IL-6 by mast cells, and the maturation of hematopoietic progenitor cells (8, 9, 13) . IL-9 also induces the production of IL-8, IL-13, and eotaxin by airway smooth muscle cells and goblet cell metaplasia in airway epithelial cells (14) . Recently, IL-9-producing cells have also been shown to exhibit robust antitumor immunity for melanoma (15, 16) .
Like IL-9, IL-2 is a type 1 four α-helical bundle cytokine produced primarily by CD4 + T cells following antigen activation (10, 17) . IL-2 signals via intermediate or high-affinity receptors containing IL-2Rβ and the common cytokine receptor γ chain, γ c . IL-2 augments Th1 and Th2 differentiation but inhibits Th17 and T FH differentiation (18) (19) (20) (21) (22) (23) , and interestingly is known to be important for IL-9 production (24, 25) , but how IL-2 regulates Th9 differentiation and IL-9 production remains unclear.
Here we provide evidence for a direct role for the IL-2-JAK3-STAT5 signaling pathway in regulating Th9 differentiation. We also found that IL-2 and IL-21 have opposing roles in Th9 differentiation, with IL-2 promoting and IL-21 inhibiting formation of these cells, inversely correlating with their differential regulation of BCL6 expression. We also demonstrate that BCL6 binds to the STAT5 and STAT6 binding region at the Il9 locus, suggesting possible competitive binding among these factors and consistent with direct regulation of the Il9 gene by BCL6. Collectively, our results support a model in which there is an inverse relationship between BCL6 expression and Th9 differentiation, with cross-regulatory effects of IL-2 and IL-21.
Results
JAK3 and STAT5 Are Important for IL-2-Induced Il9 Expression. It was previously shown that IL-4 + TGFβ could induce IL-9 production, but this was markedly decreased in Il2 −/− T cells unless exogenous IL-2 was added (24) . We confirmed that CD4 + T cells from Il2 −/− mice indeed produced very little IL-9, and that adding IL-2 increased IL-9 production by these cells, albeit not up to WT levels (Fig. 1A) . Other γ c cytokines, including IL-7, IL-9, and IL-15, had smaller effects on IL-9 production (Fig. 1B) , even though they all, like IL-2, also activate STAT5 proteins, indicating specificity for the effect of IL-2. The requirement for IL-2 was confirmed by the ability of blocking antibodies to IL-2 + IL-2R to inhibit IL-9 production in mouse (Fig. 1C ) and human Significance Interleukin-9 (IL-9) is a γ c -family cytokine produced by Th9 cells that regulates a range of immune responses, including allergic inflammation. We show that IL-2 via STAT5 is required for Th9 differentiation. IL-2 inhibits B cell lymphoma 6 (BCL6), which inhibits Th9 differentiation, whereas IL-21 induces BCL6. BCL6 bound near STAT5 and STAT6 binding sites, including at the Il9 (gene encoding IL-9) promoter, and BCL6 binding increased and STAT binding decreased after treatment with anti-IL-2/IL-2R. Thus, IL-2 and IL-21 have opposing actions on BCL6 expression, which inversely correlates with Th9 differentiation and IL-9 production, with implications for controlling Th9 differentiation and potentially allergic inflammation. (Fig. 1D) T cells under Th9 polarizing conditions (IL-4 + TGFβ + anti-IFNγ). We next compared the kinetics of IL-2 versus IL-9 production during Th9 differentiation and found that IL-2 was produced by day 1, increased by day 3, but then declined by day 5, whereas little IL-9 was produced at day 1 but increased by day 3 (Fig. 1E) . Thus, IL-2 production precedes that of IL-9, consistent with a requirement for IL-2 early during Th9 differentiation. Because IL-2 is a T-cell growth factor, we investigated if its effect on Th9 differentiation was due to an effect on proliferation. Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) and incubated under Th9 conditions for 5 d. Both WT and Il2 −/− cells exhibited fairly similar CFSE dilution profiles (Fig. 1F, Upper) , with maximal IL-9 expression by division 2-3 (Fig. 1F, Lower) . Il9 expression in Il2 −/− T cells was less sustained, with fewer IL-9−producing cells at each cell division (Fig.  1F, Lower) . Thus, IL-2 regulates IL-9 production at least partially independent of its role in T-cell proliferation.
Because of the importance of transcription factors PU.1 and IRF4 for Th9 differentiation (26, 27) , we investigated if IL-2 affected their expression. IL-2 did not induce PU.1 mRNA over the basal level (Fig. S1A ), but it significantly enhanced Irf4 expression in preactivated CD4 + T cells, whereas IL-12 and IL-21 had no effect (Fig. S1B) , and based on RNA-Seq analysis, Il2 −/− Th9 cells had lower Irf4 mRNA expression than did WT Th9 cells (Fig. S1C and Dataset S1). Although Il9 mRNA was somewhat decreased in Irf4 −/− T cells, IL-2 could still induce substantial Il9 expression in preactivated (Fig. S1D ) and Th9-differentiated (Fig. S1E) 
Irf4
−/− T cells, indicating that IRF4 was not essential for IL-2-induced Il9 expression. Correspondingly, retroviral transduction of Irf4 did not restore normal IL-9 production in Il2 −/− T cells (Fig. S1F ). To clarify how IL-2 regulates Th9 differentiation, we next examined the signaling pathway(s) required for IL-9 expression. CD4 + T cells were cultured under Th9 conditions for 3 d, rested overnight, inhibitors were added 1 h before IL-2, and Il9 mRNA expression was measured by real-time PCR 4 h later. Whereas inhibitors of MAPK (PD183161) and NF-κB (Calbiochem no. 481406) increased IL-2-induced IL-9 production and a PI3-kinase inhibitor (LY294002) had no significant effect, a JAK3 inhibitor (CP690550) potently inhibited IL-2-induced Il9 mRNA expression (Fig. 2A) . We next examined the ability of various cytokines to induce Il9 mRNA in cells that were Th9-differentiated for 3 d and then rested overnight. Although IL-4 induced Il9 mRNA expression, consistent with its role in driving Th9 differentiation, IL-2 was more potent (Fig. 2B ). IL-2 is an activator of STAT5, whereas IL-4 activates STAT6. It was thus interesting that IL-15, which like IL-2 also activates STAT5, also induced Il9 expression more potently than IL-4, albeit less potently than IL-2 (Fig. 2B) . The weaker effect of IL-15 was consistent with its weaker effect than IL-2 on Th9 differentiation in Il2 −/− cells (Fig. 1B) . IL-21, which primarily uses STAT3, did not induce and in fact decreased Il9 mRNA expression (Fig. 2B ). To investigate the importance of STAT5, we deleted the Stat5a and Stat5b genes using Cre recombinase and Stat5 fl/fl T cells (Fig. 2C ) and found markedly decreased IL-9-producing cells after Th9 polarization (Fig. 2 D and E) as well as a decreased ability of IL-2 to induce Il9 mRNA expression (Fig. 2F) . Thus, STAT5 is necessary for the normal increase in IL-9-producing cells during Th9 differentiation.
GAS Motifs in the Il9 Promoter Bind STAT5 and Mediate IL-2-Induced
Il9 Expression. STAT5 potentially can act directly at the Il9 locus and/or have indirect effects. To investigate a direct effect, we performed ChIP-Seq experiments during Th9 polarization. Weak STAT5 ChIP-Seq peaks were observed in the Il9 gene at 16 h, but strong peaks were observed after two rounds of Th9 differentiation (Fig. 3A) , with STAT6 binding at similar positions (Fig. 3A) . We separately cloned the Il9 promoter and upstream regions with the strongest STAT5 binding based on ChIP-Seq analysis (see Fig. S2 for sequences) into pGL4.23, a luciferase reporter vector with a minimal promoter, and constructs were transfected into CD4 + T cells. The upstream region did not exhibit activity, but the Il9 promoter was induced potently by IL-2 and weakly by IL-4 but not by TGF-β, and IL-2 + IL-4 gave higher activity than IL-2 alone (Fig. 3B) . The Il9 promoter region has two gamma interferon activation site (GAS) motif regions (Fig. 3C, Upper) , and mutation of either the GAS1 or GAS2 motifs diminished promoter activity, whereas mutation of both essentially abrogated activity (Fig. 3C , Lower). Thus, IL-2 directly induces STAT5-dependent Il9 transcription via binding sites in the Il9 promoter.
IL-21 Inhibits Th9 Differentiation. Above, we found that Il9 mRNA expression was decreased by IL-21, in contrast to its marked increase in IL-2-treated cells (Fig. 2B) . Consistent with this, IL-21 potently inhibited Th9 differentiation, with fewer IL-9-producing cells (Fig. 4A) . Correspondingly, Il21r −/− (Fig. 4B ) and Il21 −/− (Fig. 4C ) T cells exhibited greater Th9 differentiation, and adding IL-21 to Il21 −/− T cells markedly decreased Il9 mRNA expression (Fig. 4C) . Interestingly, however, IL-21 did not diminish either anti-CD3/CD28 or anti-CD3/CD28 + IL-2-induced Il9 reporter activity (Fig. 4D) ; thus, the effect of IL-21 was indirect rather than a direct effect on the Il9 promoter.
Opposing Actions of IL-2 and IL-21 on Th9 Differentiation Correlate with Their Differential Regulation of BCL6 Expression. Because of opposing actions of IL-2 and IL-21 in Th9 differentiation, we sought to identify factors that were differentially regulated by these cytokines. By performing time-course RNA-Seq experiments during Th9 differentiation, we found that 906 transcription factors were expressed when we used a threshold level of gene expression of reads per kilobase per million (RPKM) > 1 at one or more time points in naïve cells versus cells Th9-polarized for 1, 4, 8, 17, 24, 72, or 168 h (two rounds of polarization). To examine which of these factors are bound by STAT5B early in Th9 differentiation, we analyzed STAT5B ChIP-Seq data at 16 h of Th9 differentiation. We identified 283 STAT5B binding sites (peaks) within a total of 173 genes (Fig. 5A , black circle), of which 22 encode transcription factors that are expressed in Th9 cells (intersection of black and light gray circles; binding locations of STAT5B in these genes are in Fig. 5B and Dataset S2). To determine if these genes are regulated by IL-2 and/or IL-21 in preactivated CD4
+ T cells, quantitative RT-PCR was performed for select genes that were differentially expressed in Il2 +/+ versus Il2 −/− Th9 cells (Dataset S1) with proximal STAT5B sites (within 5 kb of transcription start sites) and P value < 10 −7 for STAT5B binding (Fig. 5 C-H ). Of six genes tested (Runx1, Mllt6, Arid5b, Ikzf3, Ikzf4, and Bcl6), Bcl6 had the highest STAT5B binding intensity (tag number) (Fig. S3F) . Moreover, when we examined the expression levels of these genes (Fig. 5 C-H), we found that IL-2 significantly augmented expression of Arid5b (Fig. 5E ) and Ikzf4 (Fig. 5G ) but decreased expression of Bcl6 (Fig. 5H) , and IL-21 most markedly increased expression of Bcl6, indicating opposing roles for IL-2 and IL-21 in regulating BCL6 expression, analogous to their opposing effects on Th9 differentiation. Because the ability of IL-21 to induce BCL6 has been reported in other settings (28, 29) , we examined the effect of IL-2 and IL-21 on Bcl6 expression in Th9-polarized cells and found that IL-21 increased Bcl6 (Fig. 5I ) but decreased Il9 (Fig. 5J) , whereas IL-2 repressed Bcl6 (Fig. 5I ) but increased Il9 (Fig. 5J) , and when IL-2 and IL-21 were combined, Bcl6 (Fig. 5I) and Il9 (Fig. 5J ) expression levels were similar to those observed with IL-2 alone, suggesting that IL-2 had a dominant effect over IL-21. When we examined the expression level of Bcl6 in Th1, Th2, Th9, and Th17 cells, we found that Th9 cells had the lowest expression (Fig. 6A) . A time course analysis of Th9-differentiated cells inversely correlated Il9 and Bcl6 expression (Fig. 6B) . Moreover, RNA-Seq and RT-PCR revealed high Il9 and very low Bcl6 expression in Th9-polarized WT cells but very low Il9 and high Bcl6 expression in Th9 polarized Il2 −/− cells (Fig. 6 C and D and Dataset S1), consistent with a negative regulatory role for BCL6 in Th9 differentiation. Importantly, the percentage of BCL6 + cells dramatically increased when IL-2 signaling was blocked with antibodies to IL-2 and IL-2R, and virtually no BCL6
+ cells coexpressed IL-9 (Fig. 6E) . Moreover, retrovirally mediated overexpression of BCL6 (Fig. 6F) decreased both basal and IL-2-induced Il9 expression (Fig. 6G) , indicating an effect of BCL6 on IL-9 expression. We hypothesized that if BCL6 indeed mediated decreased IL-9 expression by IL-21, then IL-21 should not diminish Th9 differentiation in the absence of BCL6. Indeed, in cells subjected to Th9 differentiation, IL-21 inhibited IL-9 production by Bcl6 +/+ cells but not by Bcl6 −/− cells (Fig. 6H) . Consistent with these results, when we lowered Bcl6 expression by introducing a Bcl6 shRNA into WT cells (Fig. 6I) we found that IL-21 did not diminish IL-9 production (Fig. 6 J and K) . 
Interestingly, in both Bcl6
−/− T cells or WT T cells that received BCL6 shRNA, the percentage of IL-9-producing cells was not increased following Th9 differentiation. Combining this result with our observation that Bcl6 expression is very low in Th9 cells (Fig. 6 B-D) , it appears that BCL6 can repress Th9 differentiation/IL-9 production, but that the lack of BCL6 per se is not a sufficient driving force to enhance Th9 differentiation.
Binding of BCL6 and STAT5/STAT6 at Similar Locations at the Il9
Promoter. To investigate the mechanism(s) by which BCL6 affects IL-9 production, we generated BCL6 ChIP-Seq libraries from Th9 cells differentiated in the presence or absence of blocking antibodies to IL-2 and IL-2R. We found that BCL6 bound to 1,157 binding sites (in 629 genes) that also bound STAT5B and STAT6 (Fig. 7A and Dataset S3), including at the Il9 promoter (Fig. 7B) . BCL6 binding increased, whereas STAT5B and STAT6 binding decreased, when blocking antibodies to IL-2 and IL-2R were added (Fig. 7B and Fig. S4 ). Importantly, BCL6 exhibited higher binding at the Il9 promoter when cells were subjected to Th9 differentiation conditions in the presence of IL-21 (Fig. 7C) . These data suggest that BCL6 may impair IL-9 production by competing with STAT5/STAT6 binding, although direct competition has not yet been demonstrated, and lowering BCL6 expression allows efficient Th9 differentiation. The ability of anti-IL-2/anti-IL-2R to diminish STAT5 binding was expected; however, its ability to diminish the binding of STAT6, which is activated by IL-4, indicates that anti-IL-2/anti-IL-2R blockade may be inhibiting the general Th9 differentiation program, consistent with the role of IL-2 in regulating IL-4Rα expression (23) .
Discussion
Th9 cells are involved in allergic inflammation and immunity to intestinal parasites (6-9) and also have been reported to exhibit robust tumor immunity to melanoma (16) . IL-2 was shown to play an important role in promoting production of IL-9 (24), but the mechanism has been unclear. We now have shown that IL-2 not only directly regulates IL-9 expression via STAT5 binding to the Il9 promoter, but it decreases expression of BCL6. In contrast, IL-21 induced expression of BCL6 and diminished IL-9-producing cells. These results suggest that IL-2 and IL-21, two γ c family cytokines, serve counterbalancing roles in Th9 differentiation. While this study was under review, another study demonstrated that thymic stromal lymphopoietin (TSLP)-induced STAT5 also contributes to Il9 expression, providing additional insights into the complex control of Th9 differentiation (30) .
BCL6 has essential roles in B-cell and T-cell biology and is highly expressed in germinal center B cells as well as in differentiating and activated B cells (31) and T FH cells (29, 32, 33) . In this study, we propose an additional role for BCL6-namely, the ability to modulate Th9 differentiation and IL-9 production. We found that BCL6 binds to many sites where STAT5/STAT6 can also bind, including at the Il9 promoter, consistent with the possibility that BCL6 might compete with STAT5 and STAT6 binding and alter regulation of the corresponding genes. BCL6 has also been reported to block TGFβ signaling by repressing the transcriptional activity of SMAD3/4 (34), and SMAD3 has been shown to contribute to IL-9 production (35). However, in Bcl6 −/− T cells and in WT T cells transfected with BCL6 shRNA and subjected to Th9 differentiation, the percentage of IL-9-producing cells was not increased, suggesting that merely lowering BCL6 is not sufficient to induce Th9 differentiation, but differential regulation by IL-2 and IL-21 of BCL6 and perhaps other factors creates an environment favorable or unfavorable for Th9 differentiation.
IL-2 and IL-21 exert major actions on a range of lymphoid populations, and in some cases they have opposing effects, for example related to Th17 and T FH differentiation where IL-21 promotes but IL-2 inhibits their differentiation (18, 21, 36, 37) . It was suggested that competition of IL-2-induced STAT5 for STAT3 binding sites in the Il17a gene locus mediated IL-2's inhibition of Il17a transcription (38) , although other effects of IL-2, including its repression of gp130 and induction of T-box transcription factor Tbx21 (T-bet), have also been proposed (22) . BCL6 has been shown to be critical for T FH differentiation and germinal center formation, and IL-2 and IL-21 play different roles in T FH formation by differentially regulating BCL6 (18, 21, 36, 37) . Our findings related to Th9 cells together with studies on Th17 and T FH cells indicate a fine regulation of T-helper cell differentiation by IL-2 and IL-21, but in the case of Th9 cells, IL-2 instead of IL-21 promotes differentiation, and BCL6 inhibits rather than promotes the differentiation of these cells. This reciprocal regulation of Th9 versus Th17 and T FH differentiation by IL-2 versus IL-21, in part via effects on BCL6, provides unique insights in T-helper cell differentiation, with potential implications for therapeutic approaches for allergic disease and cancer. Staudt (National Cancer Institute, Bethesda) (40) . Animal protocols were approved by the National Heart, Lung, and Blood Institute (NHLBI) Animal Care and Use Committee and followed the NIH Guidelines "Using Animals in Intramural Research." Naïve CD4 + T cells were purified from spleen and lymph nodes of 5-12-wk-old mice using CD4 + CD62 + T-cell Isolation Kit II (Miltenyi). Cells were cultured in RPMI medium 1640 containing 10 mM Hepes, 100 mL/L FBS, 2 mM L-glutamine, and antibiotics, including 50 μM 2-ME, and activated with plate-bound anti-CD3 (2 μg/mL) and soluble anti-CD28 (1 μg/mL, PharMingen) or under Th9 conditions (see Th9 Polarization).
Th9 Polarization. Mouse naïve CD4 + T cells were cultured with 2 μg/mL platebound anti-CD3 + 1 μg/mL soluble anti-CD28, 40 ng/mL IL-4, 2 ng/mL TGFβ/ mL, and 10 μg/mL of anti-IFNγ. Mouse IL-4 and TGFβ were from PeproTech. Neutralizing antibodies to mouse IFNγ (XMG1.2), IL-2 (S4B6), IL-2Rα (PC61), and IL-2Rβ (TM-β1) were from BD Bioscience or BioLegend.
Quantitative RT-PC. RT-PCR was performed as described (23) . Primers and probes were from Applied Biosystems, Inc. Expression levels were normalized to Rpl7.
RNA-Seq Analysis. Sequenced reads (36 bp, single end) were mapped to the mouse genome (mm8, February 2006 Assembly) using the Illumina GA pipeline. Mapped reads were normalized by library size (reads per million) and summed in 20 bp sliding windows that were displayed on the University of California, Santa Cruz (UCSC) genome browser. Digital gene expressions were calculated by counting raw reads that fell on exons of each gene, and differentially expressed genes were identified using edgeR (41) .
ChIP-Seq and ChIP Analysis. ChIP-Seq was performed as previously described (22, 23) . Anti-STAT5B (St5B) was from R&D Systems, and anti-STAT6 (M-20, sc-981) and anti-Bcl6 (N-3, sc-858) were purchased from Santa Cruz Biotechnology. Unique sequence reads were centered on corresponding chromatin fragments, summed in 200 bp windows, and displayed as custom tracks on the UCSC genome browser. All ChIP-Seq and RNA-Seq samples were sequenced in the NHLBI Sequencing Core. The primers for Il9 promoter in ChIP assay were as follows: forward primer, 5′-TCACTTGACAAAGGCTG-TCTTA-3′, and reverse primer, 5′-AAACACAGACCTGGGCTTTCA. Statistical Analysis. Two-tailed paired t tests were performed using Prism 4.0 (GraphPad software). 
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